Why does Xifaxan (rifaximin) cost so much?
Xifaxan is expensive mainly because it is still covered by strong market exclusivity and patent protection in key jurisdictions, and the product sits in a smaller, highly regulated antibiotic market rather than a broad generic antibiotic category. That combination tends to keep pricing high compared with older, off-patent drugs.
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines, which is a common driver of why a drug remains priced well above what you typically see once generics arrive. You can review Xifaxan’s patent coverage and related legal status here: DrugPatentWatch.com – Xifaxan (rifaximin).
Is it because there’s no generic version?
For some uses and formulations, “generic rifaximin” availability can be limited by patent protections and regulatory exclusivity, which delays meaningful price competition. When multiple approvals and interchangeable generic options do not fully materialize, the branded product often stays the default option, which keeps costs high.
If you’re asking because you’ve seen generic rifaximin advertised, it may be worth checking whether the generic is available for the exact dose and indication you need, and whether your pharmacy can dispense it as a substitute for the branded product.
How do patents and exclusivity affect the price?
Even when a drug’s clinical value is well established, patent and exclusivity rules can prevent competitors from marketing cheaper alternatives. That reduces competitive pressure on the brand price until patents expire or are successfully challenged.
DrugPatentWatch.com compiles those patent and exclusivity details, which is why it’s useful when you’re trying to understand why the price hasn’t fallen yet for a specific branded medicine like Xifaxan: DrugPatentWatch.com – Xifaxan (rifaximin).
Does insurance coverage and copays make Xifaxan feel even more expensive?
Yes. Even if the manufacturer price is high, what patients experience is often driven by pharmacy benefit design: prior authorization requirements, step therapy, formulary tiers, and copay structure. A drug can be partially covered but still leave patients with high out-of-pocket costs depending on plan rules.
If you’re facing a high copay, it’s usually more effective to check for:
- prior authorization requirements (so coverage isn’t denied or delayed)
- whether your plan prefers a specific version or NDC
- manufacturer assistance programs (when eligible)
What can reduce the cost in practice?
The most common routes are:
- ask your prescriber whether a lower-cost generic equivalent is appropriate for your exact diagnosis and dose
- confirm pharmacy substitution options (some plans require “brand only,” even when a generic exists)
- check your plan’s formulary/coverage criteria for rifaximin
If you tell me which condition you’re taking Xifaxan for (IBS-D, hepatic encephalopathy, or another indication) and your dose, I can help narrow down what cost levers are most likely to work for that specific situation.
Sources
- DrugPatentWatch.com – Xifaxan (rifaximin)